市場調查報告書
商品編碼
1471183
高內容篩檢市場:按產品、應用和最終用戶分類 - 2024-2030 年全球預測High Content Screening Market by Product (Accessories, Consumables, Instruments), Application (Explorative Screening, Neurobiology, Oncology), End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
高內容篩檢市場規模預計到2023年為9.0359億美元,預計到2024年將達到100095萬美元,到2030年將達到191719萬美元,複合年成長率為11.34%。
高內涵篩檢(HCS) 是一種用於生物研究和藥物發現的強大且多功能的技術,專注於細胞內複雜生物過程的定量分析。這種方法結合了高解析度顯微鏡、自動影像分析和複雜的軟體,能夠在細胞和亞細胞層面同時分析多個生化和型態參數。疾病的日益複雜性和對更有效藥物的需求不斷成長,增加了對 HCS 的需求。慢性病的增加以及藥物發現和藥物開發活動的進步正在推動 HCS 的採用。隨著焦點轉向個人化醫療,對能夠分析單一細胞對藥物反應的技術的需求日益成長。 HCS 透過評估患者來源的細胞來促進這一點,從而有助於制定更有針對性的治療方法。然而,HCS 實驗產生的大量資料需要先進的分析工具和強大的計算能力,從而導致資料管理和解釋的複雜性。此外,很難將 HCS 系統與現有實驗室工作流程整合並確保與其他技術的兼容性,並且沒有標準化的通訊協定來比較不同平台和實驗室的臨床結果。然而,主要企業正在探索在 HCS 中使用 AI/ML 來改變資料分析,從而更聰明、更快速地解釋複雜的資料集,並為藥物發現開闢新的可能性。 3D細胞培養模型在HCS實驗中的使用也顯示出巨大的潛力。
主要市場統計 | |
---|---|
基準年[2023] | 90359萬美元 |
預測年份 [2024] | 10.95億美元 |
預測年份 [2030] | 1,917.19百萬美元 |
複合年成長率(%) | 11.34% |
產品設備對先進自動化和影像處理能力的需求日益成長
高內涵篩檢系統的附件是設計用於增強或支援主設備功能的輔助組件。這包括成像板、樣品架和流體系統,可自動處理試劑和樣品。消耗品是 HCS 過程中使用的需要定期更換的物品。此類別包括試劑、檢測套件、微孔盤和其他執行高內涵篩檢檢測所需的材料。消耗品對於 HCS 實驗的持續運作至關重要,因為它們直接影響所收集資料的品質和可靠性。微孔盤是多孔孔盤,通常由聚苯乙烯或聚丙烯製成,允許以緊湊且高效的形式同時測試多個樣品和條件。試劑和檢測試劑套件是 HCS 中的關鍵消耗品,旨在實現各種生物標的和活性的檢測、定量和分析。這些消耗品包括專為特定檢測量身定做的螢光染料、抗體、基材和緩衝液。該設備包括自動顯微鏡、影像細胞儀和用於執行篩檢過程的整合 HCS 平台。這些儀器能夠處理大量樣品並獲取高解析度影像以進行後續分析。細胞成像和分析系統將先進的顯微鏡與自動影像擷取、處理和分析功能整合在一起。流式細胞儀分析液體中生物顆粒通過至少一個雷射時的物理和化學特性。與高內涵篩檢相關的服務包括系統安裝、培訓、維護和維修支持,以及檢測開發和最佳化的諮詢服務。此外,CRO(委外研發機構)提供 HCS 作為服務,使他們無需內部設備或專業知識即可利用該技術。軟體是 HCS 流程的基礎,使您能夠控制設備、管理資料並分析結果。高內涵篩檢軟體包括影像分析程式、資料視覺化工具、統計分析套件等。解釋 HCS 系統產生的大量資料,並將原始影像轉化為有意義的生物學見解。
應用癌症研究固有的複雜性以及有效癌症治療快速發展的需求正在推動 HCS 的採用。
探索性篩檢涉及高通量尋找具有新穎生物相互作用和潛在治療效果的化合物。 HCS 透過允許針對多個細胞模型篩檢大量化合物庫,促進新標靶的識別。 HCS 可以提供詳細的多參數資料,使得根據細胞反應選擇有希望的候選化合物的過程更加細緻,並已成為早期藥物發現的基本步驟。在神經生物學中,HCS 用於闡明複雜的神經元過程,例如神經發生、突觸形成和神經元連接。這使得研究人員能夠篩檢潛在的神經保護和神經毒性化合物,研究細胞層面的疾病病理學,並評估與神經系統疾病相關的遺傳因素。在腫瘤學中,HCS 廣泛用於抗癌藥物的鑑定和檢驗。 HCS 有助於分析各種狀態的癌細胞,包括它們對藥物治療的反應,有助於了解癌細胞的增殖、遷移、侵襲和凋亡。此技術可以分析細胞形狀、大小和生物標記表達等多個參數,在評估癌細胞異質性和腫瘤組織的複雜環境方面特別有價值。標靶驗證是藥物開發平臺中的關鍵階段,HCS 在確認新標靶的相關性和特異性方面發揮關鍵作用。透過提供對標靶修飾的細胞和分子反應的高品質表現型分析,HCS 可以幫助早期消除安全性不佳或治療相關性不足的標靶。在毒理學中,HCS 用於早期篩檢化合物的細胞毒性作用。 HCS 提供對藥物引起的毒性的詳細評估,包括細胞層面的作用機制,例如粒線體功能障礙、DNA 損傷和氧化壓力。此應用對於化妝品行業的藥物安全評估、環境毒性評估和測試至關重要,確保只有安全的化合物才能進入臨床試驗。
區域洞察
以美國和加拿大為中心的美洲地區在全球 HCS 市場中佔有重要地位。該地區的主導地位是由大型製藥公司、尖端研究機構和大量醫療保健支出的存在所推動的。美國是生物醫學研究和藥物發現領域的領先國家,非常注重技術創新。美國已提交了大量 HCS 技術專利申請,反映出動態的研究環境和生命科學領域的巨大投資。 FDA 對推進藥物發現過程的支持將進一步刺激技術的採用。藥物發現中對高通量技術的需求以及支持創新醫療保健解決方案的法律規範推動了 HCS 在歐洲的採用。英國、德國和法國等國家走在前列,在生命科學和研究基礎建設上投入大量資金。 MEA 地區前景廣闊,對先進診斷和治療研究的興趣日益濃厚,這表明 HCS 技術市場正在快速成長。在快速擴張的製藥和生物技術產業(尤其是中國、日本和印度)的推動下,亞太地區正在成為充滿活力的高內涵篩檢(HCS) 技術中心。中國處於利用 HCS 技術進行藥物發現和毒性研究的前沿。日本是精準醫學和再生醫學的先驅,利用 HCS 進行幹細胞研究和藥物開發。印度已明顯轉向複雜的研發,重點在於效率和成本效益。
FPNV定位矩陣
FPNV定位矩陣對於評估高內容篩檢市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對高內容篩檢市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 高內容篩檢市場的市場規模與預測為何?
2.在高內涵篩檢市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3. 高內容篩檢市場的技術趨勢和法規結構是什麼?
4.高內涵篩檢市場主要廠商的市場佔有率為何?
5.進入高內涵篩檢市場的合適型態和策略手段是什麼?
[187 Pages Report] The High Content Screening Market size was estimated at USD 903.59 million in 2023 and expected to reach USD 1,000.95 million in 2024, at a CAGR 11.34% to reach USD 1,917.19 million by 2030.
High content screening (HCS) is a powerful and versatile technology used in biological research and drug discovery, emphasizing the quantitative analysis of complex biological processes within cells. This approach combines high-resolution microscopy, automated image analysis, and sophisticated software to enable the simultaneous analysis of multiple biochemical and morphological parameters at the cellular and subcellular levels. The growing complexity of diseases and the increasing need for more effective drugs drive the need for HCS. The growing incidences of chronic diseases and a need for advancing drug discovery and development activities have propelled the adoption of HCS. As the focus shifts towards personalized medicine, there is a growing need for technologies that can analyze individual cellular responses to drugs. HCS facilitates this by enabling the assessment of patient-derived cells, thus contributing to more tailored therapeutic approaches. However, the vast amount of data generated by HCS experiments requires sophisticated analysis tools and substantial computational power, posing complexities in data management and interpretation. Furthermore, integrating HCS systems with existing laboratory workflows and ensuring compatibility with other technologies can be challenging, and the lack of standardized protocols makes it difficult to compare clinical results across different platforms and laboratories. However, key players are exploring the utilization of AI/ML in HCS to transform data analysis, enabling more sophisticated and faster interpretation of complex datasets, thus providing new possibilities in drug discovery. The use of 3D cell culture models in HCS experiments also represents a significant opportunity.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 903.59 million |
Estimated Year [2024] | USD 1,000.95 million |
Forecast Year [2030] | USD 1,917.19 million |
CAGR (%) | 11.34% |
Product: Growing need for the advanced automation and imaging capabilities of instruments
Accessories for high content screening systems are supplementary components designed to enhance or support the functionality of the primary instruments. These can include imaging plates, sample holders, and fluidics systems that enable the automated handling of reagents and samples. Consumables are items that are used up during the HCS process and need regular replacement. This category includes reagents, assay kits, microplates, and other materials essential for conducting high content screening assays. Consumables are vital for the ongoing operation of HCS experiments, as they directly impact the quality and reliability of the data collected. Microplates are multi-well plates, typically made from polystyrene or polypropylene, which allow for the simultaneous testing of multiple samples or conditions in a compact and efficient format. Reagents and assay kits are critical consumables in HCS, designed to enable the detection, quantification, and analysis of various biological targets and activities. These consumables include fluorescent dyes, antibodies, substrates, and buffer solutions tailored for specific assays. Instruments encompass automated microscopes, image cytometers, and integrated HCS platforms that execute the screening process. These instruments are capable of handling large volumes of samples and acquiring high-resolution images for subsequent analysis. Cell imaging and analysis systems integrate advanced microscopy with automated image acquisition, processing, and analysis capabilities. Flow cytometers analyze the physical and chemical characteristics of biological particles in a fluid as they pass through at least one laser. Services related to high content screening include support for system installation, training, maintenance, and repair, as well as consulting services for assay development and optimization. Additionally, contract research organizations (CROs) offer HCS as a service, providing access to this technology without the need for in-house instruments and expertise. Software is fundamental to the HCS process, allowing for the control of instruments, management of data, and analysis of results. High content screening software includes image analysis programs, data visualization tools, and statistical analysis packages. It interprets the vast amounts of data generated by HCS systems, turning raw images into meaningful biological insights.
Application: Inherent complexity of oncology studies critical need for rapid advancement in effective cancer therapies driving adoption of HCS
Explorative screening involves the high-throughput search for novel biological interactions or compounds with potential therapeutic effects. Here, HCS facilitates the identification of new targets by enabling the screening of vast libraries of compounds against multiple cellular models. Its ability to provide detailed, multiparametric data allows for a more nuanced selection process of promising candidates based on cellular responses, making it a fundamental step in early-stage drug discovery. In neurobiology, HCS is employed to dissect complex neuronal processes, including neurogenesis, synaptogenesis, and neural connectivity. It allows researchers to screen potential neuroprotective or neurotoxic compounds, study disease pathology at a cellular level, and evaluate genetic factors involved in neurological disorders. Oncology utilizes HCS extensively for the identification and validation of anti-cancer drugs. By facilitating the analysis of cancer cells in various conditions, including response to drug treatments, HCS helps in understanding cancer cell proliferation, migration, invasion, and apoptosis. The technology's capability to analyze multiple parameters, such as cell shape, size, and biomarker expression, is particularly valuable in assessing the heterogeneity of tumor cells and the complex environment of tumor tissues. Target validation is a crucial phase in the drug development pipeline where HCS plays a vital role in confirming the relevance and specificity of novel targets. Through high-content, phenotypic characterization of cellular and molecular responses to target modulation, HCS aids in the early elimination of targets with undesirable safety profiles or insufficient therapeutic relevance. In toxicology, HCS is employed for early-stage screening of compounds for cytotoxic effects. It provides a detailed assessment of drug-induced toxicity, including mechanisms of action at the cellular level, such as mitochondrial dysfunction, DNA damage, and oxidative stress. This application is critical for pharmaceutical safety assessments, environmental toxicity evaluations, and cosmetic industry testing, ensuring that only safe compounds proceed to clinical trials.
Regional Insights
The Americas, predominantly led by the U.S. and Canada, hold a significant presence in the global HCS market. The region's dominance is fueled by the presence of leading pharmaceutical companies, cutting-edge research institutions, and substantial healthcare expenditure. The United States stands out as a key nation in biomedical research and drug discovery, with a strong emphasis on innovation. The country has seen numerous patents filed in HCS technology, reflecting a dynamic research environment and a substantial investment in life sciences. The FDA's support for advancing drug discovery processes further stimulates technological adoption. The adoption of HCS in Europe is driven by the need for high-throughput technologies in drug discovery and the strong regulatory framework supporting innovative healthcare solutions. Countries such as the UK, Germany, and France are at the forefront, witnessing considerable investment in life sciences and research infrastructure. The MEA region shows promise with an increasing interest in advanced diagnostics and therapeutic research, indicating a burgeoning market for HCS technologies. The APAC region is emerging as a vibrant hub for high content screening (HCS) technologies, driven by rapidly expanding pharmaceutical and biotechnology sectors, particularly in China, Japan, and India. China is at the forefront of leveraging HCS technologies for drug discovery and toxicology studies. Japan pioneers precision and regenerative medicine, utilizing HCS in stem cell research and pharmaceutical development. In India, there is a visible shift towards sophisticated R&D practices, with an increasing emphasis on efficiency and cost-effectiveness, which is propelling the need for HCS solutions.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the High Content Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the High Content Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the High Content Screening Market, highlighting leading vendors and their innovative profiles. These include Advanced Solutions, Inc., Agilent Technologies, Inc., Aurora Biomed Inc., Axxam S.p.A, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Charles River Laboratories International, Inc., Corning Incorporated, Creative Biolabs., Danaher Corporation, Evident Corporation, GE Healthcare, Genedata AG, Hamamatsu Photonics K.K., Merck KGaA, Ncardia Services B.V., Nikon Instruments Inc., Perkinelmer, Inc., Sartorius AG, Shimadzu Scientific Instruments, SPT Labtech Ltd., Tecan Trading AG, Thermo Fisher Scientific Inc., Yokogawa Electric Corporation, and Zeiss Group.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the High Content Screening Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the High Content Screening Market?
3. What are the technology trends and regulatory frameworks in the High Content Screening Market?
4. What is the market share of the leading vendors in the High Content Screening Market?
5. Which modes and strategic moves are suitable for entering the High Content Screening Market?